[
    [
        {
            "time": "2018-07-26",
            "original_text": "格隆汇港股聚焦(7.26)︱融创中国料上半年净利同比增逾45% 中信建投上半年净利升37.61%至23.3亿元",
            "features": {
                "keywords": [
                    "融创中国",
                    "净利增长",
                    "中信建投",
                    "上半年业绩"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "房地产",
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "格隆汇港股聚焦(7.26)︱融创中国料上半年净利同比增逾45% 中信建投上半年净利升37.61%至23.3亿元",
                "Correlation": 8,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 6,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "复星医药：子公司获临床试验通知书",
            "features": {
                "keywords": [
                    "复星医药",
                    "临床试验",
                    "子公司"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：子公司获临床试验通知书",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "复星医药控股子公司收到国家药品监督管理局签发的《临床试验通知书》",
            "features": {
                "keywords": [
                    "复星医药",
                    "临床试验",
                    "国家药品监督管理局"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药控股子公司收到国家药品监督管理局签发的《临床试验通知书》",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 4,
                "Time_Proximity": 8,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "复星医药(600196.SH)：重组人促红素-HyFc融合蛋白注射液用于治疗肾性贫血获准开展临床试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "重组人促红素",
                    "肾性贫血",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(600196.SH)：重组人促红素-HyFc融合蛋白注射液用于治疗肾性贫血获准开展临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "复星医药(02196.HK)子公司治疗肾性贫血新药获准开展临床试验",
            "features": {
                "keywords": [
                    "复星医药",
                    "肾性贫血",
                    "新药",
                    "临床试验"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药(02196.HK)子公司治疗肾性贫血新药获准开展临床试验",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2018-07-26",
            "original_text": "同仁堂科技跌近4% 被中金降级至中性评级 投资评级恶化",
            "features": {
                "keywords": [
                    "同仁堂科技",
                    "投资评级",
                    "中金公司",
                    "降级"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "同仁堂科技跌近4% 被中金降级至中性评级 投资评级恶化",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 8,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]